31349-48-1 Usage
General Description
1-Methyl-5-nitro-2-benzimidazolebutyric acid is a chemical compound with the molecular formula C12H12N4O4. It is a derivative of the benzimidazole ring system and contains a nitro group and a carboxylic acid functional group. 1-Methyl-5-nitro-2-benzimidazolebutyric acid is often used in the synthesis of pharmaceuticals and research chemicals, and it has been studied for its potential anti-inflammatory and antioxidant properties. Additionally, 1-Methyl-5-nitro-2-benzimidazolebutyric acid has been investigated for its potential use in the treatment of various medical conditions, including cancer, inflammation, and cardiovascular diseases. It is important to handle this chemical with care, as it may have hazardous effects on human health and the environment.
Check Digit Verification of cas no
The CAS Registry Mumber 31349-48-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,1,3,4 and 9 respectively; the second part has 2 digits, 4 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 31349-48:
(7*3)+(6*1)+(5*3)+(4*4)+(3*9)+(2*4)+(1*8)=101
101 % 10 = 1
So 31349-48-1 is a valid CAS Registry Number.
31349-48-1Relevant articles and documents
Process for preparation of Bendamustine
-
, (2014/02/15)
The present invention relates to a method for preparation of alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl]butanoate (7) from 2-fluoro-5-nitroaniline, comprising the steps of: a) conversion of 2-fluoro-5-nitroaniline to 5-(2-fluoro-5-nitroanilino)-5-oxopentanoic acid (1) using glutaric anhydride, conversion of compound (1) to methylammonium 5-[2-(methylamino)-5-nitroanilino]-5-oxopentanoate (2) using methylamine; conversion of compound (2) to 5-[2-(methylamino)-5-nitroanilino]-5-oxopentanoic acid (3) and condensation of compound (3) to 4-(1-methyl-5-nitro-1H-benzimidazol-2-yl)butanoic acid (4), b) esterification of the product (4) of step a) to alkyl 4-(1-methyl-5-nitro1H-benzimidazol-2-yl)butanoate (5), c) reduction of the product of step b) to alkyl 4-(5-amino-1-methyl-1H-benzimidazol-2-yl)butanoate (6), and d) conversion of the product of step c) to alkyl 4-[5-[bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazol-2-yl]butanoate (7).
